Abstract
Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).
| Original language | English |
|---|---|
| Article number | e741 |
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Pain Reports |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 May 2019 |
Funding
a Centre for Pain Research, University of Bath, Bath, United Kingdom, b Cochrane Pain, Palliative, and Supportive Care Review Groups, Oxford University Hospitals, Oxford, United Kingdom, c Department of Clinical and Health Psychology, Ghent University, Ghent, Belgium, d National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia, e Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre and Centre for Pain Research, NCBES, National University of Ireland Galway, Galway, Ireland, f Department of Clinical Medicine, Danish Pain Research Center, Aarhus University, Aarhus, Denmark, g Department of Neurology, Aarhus University Hospital, Aarhus, Denmark, h Department of Anesthesiology and Perioperative Medicine, Kingston General Hospital, Queen’s University, Kingston, ON, Canada, i Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada, j School of Policy Studies, Queen’s University, Kingston, ON, Canada, k Division of Clinical and Translational Research, Department of Anesthesiology, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, l Department of Anesthesiology, Perioperative, and Pain Medicine, and Pediatrics, Stanford University School of Medicine, Stanford, Palo Alto, CA, m Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom, n Department of Anesthesia, University of California, San Francisco, CA, o Sutter Health, CPMC Research Institute, California Pacific Medical Center Research Institute, San Francisco, CA, p Division of Pain Medicine, Department of Anesthesiology, University of California San Diego, San Diego, CA, q Pain Research, Nuffield Department of Clinical Neurosciences, The Churchill, University of Oxford, Oxford, United Kingdom *Corresponding author. Address: Centre for Pain Research, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom. Tel.: 01225 384076. E-mail address: [email protected] (E. Fisher). Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.painrpts.com). Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. L. Degenhardt reports grants from Indivior and grants from Seqirus, outside the submitted work. D.P. Finn reports grants from Randox Ltd, grants from Alkermes, Inc, and grants from Shionogi Ltd, outside the submitted work. N.B. Finnerup reports personal fees from Grünenthal, personal fees from Teva Pharmaceuticals, personal fees from Astellas, personal fees from Novartis Pharma, personal fees from Mitsubishi Tanabe Pharma, personal fees from Merck, grants from PainCare, IMI2 (Innovative medicines initiative), which is a EU public–private consortium with a grant provided by the EU and the companies involved are: Grunenthal, Bayer, Eli Lilly, Esteve, Novartis, and Teva, outside the submitted work. I. Gilron reports personal fees from Adynxx, personal fees from Biogen, personal fees from Eupraxia, personal fees from Novaremed, personal fees from Teva, nonfinancial support from Canopy Health, nonfinancial support from Toronto Poly Clinic, and nonfinancial support from CannTrust, outside the submitted work. S. Har-outounian reports grants from Pfizer Inc and personal fees from Medoc Ltd, outside the submitted work. A.S.C. Rice is part of the Presidential Task Force of the IASP, during the conduct of the study; personal fees from Imperial College Consultants, other from Spinidex/Novartis, outside the submitted work. In addition, A. Rice has a patent: Rice A.S.C, Vandevoorde S., and Lambert D. M Methods using N-(2propenyl)hexadecanamide and related amides to relieve pain. WO2005/079771 pending, and a patent Okuse K. et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/WO2013 110945 pending. M. Wallace reports personal fees from Insys, outside the submitted work. R.A. Moore reports personal fees from Novartis and personal fees from RB, outside the submitted work. The remaining authors have no conflicts of interest to declare. Cochrane Review Group funding acknowledgement: this project was partly supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Pain, Palliative, and Supportive Care Review Group (PaPaS). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.
Keywords
- Cannabinoids
- Cannabis
- Meta-analysis
- Overview
- Pain
- Protocol
- Systematic review
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Fingerprint
Dive into the research topics of 'Cannabinoids, cannabis, and cannabis-based medicine for pain management: A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials'. Together they form a unique fingerprint.Profiles
-
Emma Fisher
- Department for Health - Senior Research Fellow
- Centre for Pain Research
- Bath Institute for the Augmented Human
- Centre for Motivation and Health Behaviour Change
Person: Researcher, Affiliate staff